Emerging therapy options may help patients with RAG deficiency, especially those with severe immune dysregulation

Moataz Dowaidar

DOI: https://doi.org/10.31219/osf.io/v5tjg

2021-06-10

Abstract:New understandings about RAG1 and RAG2 gene expression have recently been gained. Rag expression molecular pathways are now known to support research on genetic variants that influence regulatory domains for lymphoid development. The RAG1/RAG2 complex might serve as a model for RAG alterations in vivo and in vitro recombination experiments. These data indicate the approximate relationship between RAG deficiency genotype and phenotype. Although this concept has not yet been proven, it is theorized that hypomorphic RAG mutations restrict RAG complexes and interfere with appropriate T-and B-cell development.A unique cellular and animal model has uncovered significant immunological and clinical insights regarding RAG mutations. Rag mutations causing below-normal levels of T and B cell development have considerable ramifications on thymic lymphostromal cross talk as well as on receptor editing in the bone marrow and on the survival of self-reactive peripheral B cells. These difficulties account for the higher occurrence of autoimmune symptoms in people and animals with hypomorphic RAG mutations. A study looking at human T cell development used the in vitro methodology to investigate RAG-mutant mice. Finally, emerging therapy options may help patients with RAG deficiency, especially those with severe immune dysregulation. Useful therapy could benefit other people with immune inborn errors as well.New exploratory approaches are emerging to help cure RAG deficiency. These techniques have offered a distinct understanding of RAG deficiencies employing artificial thymic organoids (ATOs) and induced pluripotent stem cells, respectively (iPSCs). novel possible therapeutic approaches, such as lentiviral vector‐mediated gene therapy, gene editing, and nongenotoxic conditioning regimens for hematopoietic stem cell transplantation (HSCT).